Clinical Trials Manager
I am the SITU Trials Manager in NDS at the University of Oxford. I obtained a PhD degree in Non-Viral Gene Therapy from the School of Chemistry, University of Birmingham. After my PhD I worked as formulation scientist at Aphton Corporation and led the formulation team at Glide Pharma. At Glide Pharma I was highly involved in setting up and running 2 Phase 1 clinical trials including the GMP manufacture of the CTIMP. I joined NDORMS in 2010 and managed the multi-centre vasculitis study, TABUL (Chief Investigator - Prof Raashid Luqmani), I am also a member of the Oxford C Ethics Committee. I joined SITU in November 2014.
Setting up clinical research studies in the National Health Service in England
Whitburn J. et al, (2017), Journal of Clinical Urology, 10, 145 - 147
HISTOLOGY FINDINGS IN GIANT CELL ARTERITIS (GCA) AND THEIR RELATIONSHIP WITH THE ULTRASOUND RESULTS: ANALYSIS OF DATA FROM THE TABUL STUDY (TEMPORAL ARTERY BIOPSY VS ULTRASOUND IN DIAGNOSIS OF GIANT CELL ARTERITIS)
Ponte CB. et al, (2017), RHEUMATOLOGY, 56, 56 - 57
Is vascular endothelial growth factor a useful biomarker in giant cell arteritis?
Goodfellow N. et al, (2017), RMD Open, 3
The Role of Ultrasound Compared to Biopsy of Temporal Arteries in the Diagnosis and Treatment of Giant Cell Arteritis (TABUL): a diagnostic accuracy and cost-effectiveness study.
Luqmani R. et al, (2016), Health Technol Assess, 20, 1 - 238
VASCULAR ENDOTHELIAL GROWTH FACTOR AS AN AID TO DIAGNOSIS OF GIANT CELL ARTERITIS
Goodfellow N. et al, (2016), ANNALS OF THE RHEUMATIC DISEASES, 75, 435 - 436